PD-1 inhibitor combined with chemotherapy versus bevacizumab combined with chemotherapy as first-line treatments for advanced non-squamous non-small cell lung cancer:a retrospective study
10.12354/j.issn.1000-8179.2024.20240989
- VernacularTitle:PD-1抑制剂联合化疗对比贝伐珠单抗联合化疗一线治疗非鳞非小细胞肺癌的研究
- Author:
Zheng FEI
1
;
Li SHUGUANG
;
Huang FANG
;
Shi JIAN
;
Liu YIBING
Author Information
1. 河北医科大学第四医院肿瘤内科(石家庄市 050011)
- Keywords:
PD-1 inhibitor;
bevacizumab;
non-squamous non-small cell lung cancer(nsNSCLC)
- From:
Chinese Journal of Clinical Oncology
2024;51(15):769-774
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy of programmed death-1(PD-1)inhibitors combined with chemotherapy with that of bevaci-zumab combined with chemotherapy as first-line treatments for advanced non-squamous non-small cell lung cancer(nsNSCLC).Methods:Retrospective collection of 237 patients with advanced nsNSCLC who received first-line treatment at the Fourth Hospital of Hebei Medical University from November 2014 to March 2024.According to the treatment plan,119 cases were assigned into PD-1 inhibitor com-bined with chemotherapy(IC group)and 118 cases were assigned into bevacizumab combined with chemotherapy(BC group).Propensity score matching(PSM)was used to balance covariates.The primary endpoint was progression-free survival(PFS),and the secondary end-points were objective response rate(ORR),disease control rate(DCR),and overall survival(OS).Results:Among 237 patients with PSM,87 were assigned to the IC group and 87 to the BC group,with respective ORRs of 31.0%(27/87)and 43.7%(38/87)(P=0.085)and respective DCRs of 96.6%(84/87)and 95.4%(83/87)(P=1.000).No significant difference in the median PFS was observed between the two groups,with a PFS value of 9.3 months in the IC group and 9.1 months in the BC group(P=0.053).In addition,the two groups also showed no significant difference in OS(neither group reached the median OS;P=0.116).Conclusions:There was no significant difference in the short-term efficacy between chemotherapy combined with PD-1 inhibitor and that combined with bevacizumab as first-line treatments for advanced nsNSCLC.
